A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Key Inclusion Criteria: * Female of age 19-54 years * Clinical Diagnosis of Androgenetic Alopecia * Written informed consent Key Exclusion Criteria: * Other types of Alopecia or other diseases that can cause hair loss * Clinically significant scalp disease such as seborrheic dermatitis or psoriasis * Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator * Women who are pregnant or breastfeeding * Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug